<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05626478</url>
  </required_header>
  <id_info>
    <org_study_id>AVC-003</org_study_id>
    <nct_id>NCT05626478</nct_id>
  </id_info>
  <brief_title>Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery</brief_title>
  <official_title>Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt in Conjunction With Topical Drop Regimen Treating Pain and inflamMation Following Cataract Surgery Compared to SOC Topical Drop Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nicole Fram M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Advanced Vision Care</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt Treating Pain, and inflamMation&#xD;
      Following Cataract Surgery Compared to Topical Prednisolone Acetate 1%.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2022</start_date>
  <completion_date type="Anticipated">March 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>In patient who undergo cataract surgery, subjects will be randomized to 2 arms and be followed for a period of 3 months.&#xD;
Arm 1- control group, 50 subjects will receive Prednisolone Acetate 1% QID x 2 weeks then BID x 2 weeks.&#xD;
Arm 2 - study group, 50 subjects will receive Dextenza 0.4mg insert</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in anterior chamber inflammation (Cell and Flare) scores</measure>
    <time_frame>Assessed on Days 1,7,30,90</time_frame>
    <description>Measured by SUN (Standardization on Uveitis Nomenclature) grading scale: absence of cell to be defined as a grade of 0-0.5 and absence of flare to be defined as a grade of: 0-1. 0-4 score scale, higher scores (4) mean a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change in pain score</measure>
    <time_frame>Assessed on Day 1,7, 30 and 90</time_frame>
    <description>Measured with the visual analog scale (VAS); between 0 and 100; 0 meaning no pain and 100 meaning worst pain possible</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual outcome (Best Corrected Visual Acuity)</measure>
    <time_frame>Assessed on Day 1,7, 30 and 90</time_frame>
    <description>Measured by ETDRS (Early Treatment Diabetic Retinopathy Study) chart. 0-70 letter read score. higher scores mean a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of CME (Cystoid Macular Edema)</measure>
    <time_frame>Assessed on Day 90</time_frame>
    <description>Measured by OCT (Optical Coherence Tomography)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in corneal staining</measure>
    <time_frame>Assessed on Day 7, 30 and 90</time_frame>
    <description>measured by the National Eye Institute 0-4 score scale, higher scores (4) mean a worse outcome.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety endpoint: corneal or retinal edema</measure>
    <time_frame>Assessed throughout 90-day study period</time_frame>
    <description>Measured by slit lamp examination and supporting imaging and testing such as Pachymetry measured in micrometer (Î¼m) or Macular (Optical Coherence Tomography)</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety endpoint: Signs of Rebound Iritis</measure>
    <time_frame>Assessed throughout 90-day study period</time_frame>
    <description>Measured by slit lamp examination and scored by SUN (Standardization on Uveitis Nomenclature) grading scale: absence of cell to be defined as a grade of 0-0.5 and absence of flare to be defined as a grade of: 0-1, (0-4 score scale) higher scores (4) mean a worse outcome. (specifically sub-grouped Blue vs. Brown eyed subjects)</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety endpoint: Change in IOP (IntraOcular Pressure) initiating rescue medications</measure>
    <time_frame>Assessed throughout 90-day study period</time_frame>
    <description>Measured by Applanation in millimeter Hg(Mercury), higher then 22mm Hg or lower then 10mm Hg mean a worse outcome and a need for rescue.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Corneal Edema</condition>
  <condition>Corneal Defect</condition>
  <condition>Anterior Chamber Inflammation</condition>
  <condition>Ocular Pain</condition>
  <condition>Corneal Staining</condition>
  <condition>Visual Outcome</condition>
  <condition>CME - Cystoid Macular Edema</condition>
  <arm_group>
    <arm_group_label>Arm 1 - Cataract surgery gtt regimen per SOC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Following cataract surgery patients will receive: Prednisolone Acetate 1% QID X 2 Weeks, then BID x 2 weeks and stop / Moxifloxacin 0.5% QID X 1 Week and stop /Prolensa 0.07% QD X 4 Weeks and stop.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 - Cataract surgery with Dextenza and less frequency of gtt regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following cataract surgery with DEXTENZA, patients will receive: Moxifloxacin 0.5% QID X 1 Week and stop /Prolensa 0.07% QD X 4 Weeks and stop</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextenza 0.4Mg Ophthalmic Insert</intervention_name>
    <description>DEXTENZA 0.4Mg Ophthalmic Insert is a corticosteroid intracanalicular insert placed in the punctum, a natural opening in the eye lid, and into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives.&#xD;
Omni (yellow top) Prednisolone Phosphate 1%/Moxifloxacin 0.5%/Bromfenac 0.075%</description>
    <arm_group_label>Arm 2 - Cataract surgery with Dextenza and less frequency of gtt regimen</arm_group_label>
    <other_name>Dexamethasone 0.4mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone Acetate 1% Oph Susp</intervention_name>
    <description>Prednisolone Acetate 1% is a corticosteroid (to decrease inflammation) and being used as a topical drop after cataract surgery per Standard Of Care.</description>
    <arm_group_label>Arm 1 - Cataract surgery gtt regimen per SOC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin 0.5% Ophthalmic Solution</intervention_name>
    <description>Moxifloxacin 0.5% is an Antibiotic (to prevent infection) and is being used as a topical drop after cataract surgery per Standard Of Care.</description>
    <arm_group_label>Arm 1 - Cataract surgery gtt regimen per SOC</arm_group_label>
    <arm_group_label>Arm 2 - Cataract surgery with Dextenza and less frequency of gtt regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prolensa 0.07% Ophthalmic Solution</intervention_name>
    <description>Prolensa 0.07% is a NSAID (to decrease inflammation, swelling and pain) and is being used as a topical drop after cataract surgery per Standard Of Care.</description>
    <arm_group_label>Arm 1 - Cataract surgery gtt regimen per SOC</arm_group_label>
    <arm_group_label>Arm 2 - Cataract surgery with Dextenza and less frequency of gtt regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with clinically significant cataract and are planning to undergo&#xD;
             non-complicated Clear Cornea Incision Cataract Extraction with Posterior Capsule&#xD;
             IntraOcular Lens in one or both eyes&#xD;
&#xD;
          -  Are willing and able to comply with clinic visits and study related procedures&#xD;
&#xD;
          -  Are willing and able to sign the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Under the age of 18 at the time of signing the Informed Consent Form&#xD;
&#xD;
          -  Pregnant or planning to become pregnant during the trial period&#xD;
&#xD;
          -  Have visual acuity potential of less than 20/30 as recorded by a Retinal Acuity Meter&#xD;
             or Potential Acuity Meter glare testing&#xD;
&#xD;
          -  Have active infectious systemic disease&#xD;
&#xD;
          -  Have active infectious ocular or extraocular disease&#xD;
&#xD;
          -  Have punctal plug in the study eye&#xD;
&#xD;
          -  Have obstructed nasolacrimal duct in the study eye(s) (dacryocystitus)&#xD;
&#xD;
          -  Have known hypersensitivity to dexamethasone or are a known steroid responder&#xD;
&#xD;
          -  Have a history of ocular inflammation or macular edema&#xD;
&#xD;
          -  Has history of Laser Vision Correction (LASIK, PhotoRefractive Keratectomy) in the&#xD;
             operated eye&#xD;
&#xD;
          -  Are currently being treated with immunomodulating agents in the study eye&#xD;
&#xD;
          -  Are currently being treated with immunosuppressants and/or oral steroids&#xD;
&#xD;
          -  Are currently being treated with corticosteroid implant (i.e Ozurdex)&#xD;
&#xD;
          -  Have a history of herpes simplex virus keratitis or present active bacterial, viral,&#xD;
             or fungal keratitis in either eye&#xD;
&#xD;
          -  Have a history of complete punctal occlusion in one or both punctum&#xD;
&#xD;
          -  Currently using topical ophthalmic steroid medications&#xD;
&#xD;
          -  Are unwilling or unable to comply with the study protocol&#xD;
&#xD;
          -  Are determined by the Investigator to not be included for reasons not already&#xD;
             specified (e.g., systemic, behavioral, or other ocular disease/abnormality) if the&#xD;
             health of the subject or the validity of the study outcomes may be compromised by the&#xD;
             subject's enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicole R Fram, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Advanced Vision Care</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicole R Fram, M.D.</last_name>
    <phone>310-229-1220</phone>
    <email>nicfram@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Orly Shiler</last_name>
    <phone>310-229-1220</phone>
    <email>orlyjr@inorbit.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Advanced Vision Care</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.dextenza.com/wp-content/uploads/2019/06/NDA-208742-S001-Dextenza-labeling-19Jun19.pdf</url>
    <description>Dextenza [package insert]. Bedford, MA: Ocular Therapeutix, Inc; 2019</description>
  </link>
  <reference>
    <citation>Greenwood MD, Gorham RA, Boever KR. A Randomized Fellow-Eye Clinical Trial to Evaluate Patient Preference for Dexamethasone Intracanalicular Insert or Topical Prednisolone Acetate for Control of Postoperative Symptoms Following Bilateral Femtosecond Laser in Site Keratomileusis (LASIK). Clin Ophthalmol. 2020 Aug 6;14:2223-2228. doi: 10.2147/OPTH.S265311. eCollection 2020.</citation>
    <PMID>32821083</PMID>
  </reference>
  <reference>
    <citation>Tyson SL, Bafna S, Gira JP, Goldberg DF, Jones JJ, Jones MP, Kim JK, Martel JM, Nordlund ML, Piovanetti-Perez IK, Singh IP, Metzinger JL, Mulani D, Sane S, Talamo JH, Goldstein MH; Dextenza Study Group. Multicenter randomized phase 3 study of a sustained-release intracanalicular dexamethasone insert for treatment of ocular inflammation and pain after cataract surgery. J Cataract Refract Surg. 2019 Feb;45(2):204-212. doi: 10.1016/j.jcrs.2018.09.023. Epub 2018 Oct 24. Erratum In: J Cataract Refract Surg. 2019 Jun;45(6):895.</citation>
    <PMID>30367938</PMID>
  </reference>
  <verification_date>December 2022</verification_date>
  <study_first_submitted>November 8, 2022</study_first_submitted>
  <study_first_submitted_qc>November 15, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2022</study_first_posted>
  <last_update_submitted>December 5, 2022</last_update_submitted>
  <last_update_submitted_qc>December 5, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Advanced Vision Care</investigator_affiliation>
    <investigator_full_name>Nicole Fram M.D.</investigator_full_name>
    <investigator_title>CEO</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Corneal Edema</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

